BioCryst Pharmaceuticals | BCRX - Loan Capital


BioCryst Pharmaceuticals reported $395.2M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Chugai Pharma JPY 4.53B 1.95B Dec/2024
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
DBV Technologies USD 0 0 Mar/2025
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
Incyte USD 29.41M 785K Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novavax USD 246.3M 200K Dec/2025
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025